Skip to main
AVXL
AVXL logo

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences Corp is positioned favorably due to its demonstrated long-term clinical benefits of oral blarcamesine for Alzheimer’s disease, which outperformed matched control groups, indicating significant therapeutic potential. The company's focus on convenient once-daily dosing, particularly for its ANAVEX3-71 therapeutic candidate targeting schizophrenia, enhances patient adherence and competitive positioning as it progresses in clinical trials. Additionally, ongoing assessments revealing reductions in neuroinflammatory biomarkers support the underlying therapeutic rationale, suggesting promising avenues for addressing a substantial market need in central nervous system disorders with an estimated market value projected to reach approximately $12.6 billion by 2032.

Bears say

Anavex Life Sciences faces significant risks that contribute to a negative outlook, including the potential for negative clinical data regarding its lead candidate, blarcamesine, which is in trials for Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome. The company also confronts hurdles in securing approval for blarcamesine across its target indications and may struggle with effective commercialization if approved. Additionally, setbacks with other therapeutic candidates and concerns over long-term dilution risks further exacerbate the uncertainty surrounding Anavex's financial stability and growth potential.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.